Stimulant medication use and response to growth hormone therapy: an NCGS database analysis.

Hormone research Pub Date : 2009-01-01 Epub Date: 2009-09-01 DOI:10.1159/000232491

J Paul Frindik, Alba Morales, John Fowlkes, Stephen Kemp, Kathryn Thrailkill, Barbara Lippe, Ken Dana

{"title":"Stimulant medication use and response to growth hormone therapy: an NCGS database analysis.","authors":"J Paul Frindik, Alba Morales, John Fowlkes, Stephen Kemp, Kathryn Thrailkill, Barbara Lippe, Ken Dana","doi":"10.1159/000232491","DOIUrl":null,"url":null,"abstract":"Background/aims: Determine (1) frequency of attention-deficit hyperactivity disorder (ADHD) treatment and (2) growth responses in growth hormone (GH)-treated children who are receiving ADHD medication versus GH alone.Methods: Prepubertal children with idiopathic short stature (ISS) or GH deficiency (IGHD) enrolled in Genentech's National Cooperative Growth Study. ADHD treatment was determined by documentation of psycho-stimulant medication use at enrollment.Results: ADHD medication use increased from 0.8% (7/850) in 1985 to 5.8% (752/12,113) in 2005. First-year GH treatment response for ADHD + IGHD versus IGHD: 8.5 +/- 2.0 vs. 9.4 +/- 2.6 cm/year, but when adjusted for age, sex, and enrollment body mass index, the difference is clinically insignificant (-0.4 cm/year). First-year growth was similar in all ISS: 8.1 +/- 1.9 versus 8.6 +/- 2.1 cm/year (ADHD + ISS vs. ISS, an adjusted -0.2-cm/year difference).Conclusion: Increasing numbers of GH-treated children are taking ADHD medications and their growth responses during the first year of GH therapy are similar to those not taking ADHD medications.","PeriodicalId":13225,"journal":{"name":"Hormone research","volume":"72 3","pages":"160-6"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000232491","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000232491","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2009/9/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 13

Abstract

Background/aims: Determine (1) frequency of attention-deficit hyperactivity disorder (ADHD) treatment and (2) growth responses in growth hormone (GH)-treated children who are receiving ADHD medication versus GH alone.

Methods: Prepubertal children with idiopathic short stature (ISS) or GH deficiency (IGHD) enrolled in Genentech's National Cooperative Growth Study. ADHD treatment was determined by documentation of psycho-stimulant medication use at enrollment.

Results: ADHD medication use increased from 0.8% (7/850) in 1985 to 5.8% (752/12,113) in 2005. First-year GH treatment response for ADHD + IGHD versus IGHD: 8.5 +/- 2.0 vs. 9.4 +/- 2.6 cm/year, but when adjusted for age, sex, and enrollment body mass index, the difference is clinically insignificant (-0.4 cm/year). First-year growth was similar in all ISS: 8.1 +/- 1.9 versus 8.6 +/- 2.1 cm/year (ADHD + ISS vs. ISS, an adjusted -0.2-cm/year difference).

Conclusion: Increasing numbers of GH-treated children are taking ADHD medications and their growth responses during the first year of GH therapy are similar to those not taking ADHD medications.

查看原文本刊更多论文

兴奋剂药物的使用和对生长激素治疗的反应:NCGS数据库分析。

背景/目的:确定(1)注意缺陷多动障碍(ADHD)治疗的频率和(2)接受生长激素(GH)治疗的儿童接受ADHD药物治疗与单独接受生长激素治疗的生长反应。方法:特发性身材矮小(ISS)或生长激素缺乏症(IGHD)的青春期前儿童参加了基因泰克国家合作生长研究。ADHD治疗是通过登记时使用精神兴奋剂药物的记录来确定的。结果:ADHD药物使用率由1985年的0.8%(7/850)上升至2005年的5.8%(752/ 12113)。ADHD + IGHD与IGHD的第一年GH治疗反应:8.5 +/- 2.0 vs 9.4 +/- 2.6 cm/年，但当调整年龄、性别和入组体重指数时，差异在临床上不显著(-0.4 cm/年)。所有ISS的第一年生长相似:8.1 +/- 1.9和8.6 +/- 2.1 cm/年(ADHD + ISS与ISS，调整后的-0.2 cm/年差异)。结论:越来越多的GH治疗儿童正在服用ADHD药物，他们在GH治疗的第一年的生长反应与未服用ADHD药物的儿童相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hormone research 医学-内分泌学与代谢

自引率

0.00%

发文量